Initial Trader disappointment is attributed to the cooling off in the corporation's hugely successful treatment, Wegovy's profits. Novo Nordisk's sharp price fall pursuing its Q2 2024 results is attributed especially to slowing revenue development of Wegovy, calling for a more in-depth think about the massively well-liked therapy's quantities. P

“An important difficulty we’re confronted with is that lots of insurance coverage strategies usually are not covering drugs or other therapies for greater system weight in any way, or If they're, It is far from to a diploma that places successful therapies within attain of most of the people,” reduced Wang stated. Ozempic is usually a FDA-ac